CClinicalTrials.gg
CompletedNCT00816062VITALITYUpdated Oct 29, 2021Results posted

Post-Approval Trial of the Talent™ Abdominal Stent Graft to Treat Aortic Aneurysms

An interventional study of Talent Abdominal Stent Graft in Aortic Aneurysm, Abdominal, sponsored by Medtronic Cardiovascular. Completed at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-29.

Sponsored by Medtronic Cardiovascular · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
94
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to examine, through the endpoints established in this protocol, the long-term safety and effectiveness of the Talent Abdominal Stent Graft System, in a post-approval environment.

Read the detailed description

The Talent Abdominal Stent Graft System is a next-generation modular system for endovascular repair of Abdominal Aortic Aneurysm (AAA). The system was designed with the following enhancements: a suprarenal wire frame to provide migration resistance, and improved flexibility designed to treat difficult anatomies.

Medtronic Vascular submitted a Pre-Market Application (PMA) to the Food and Drug Administration (FDA) on October 17, 2007, and received market approval for the Talent Abdominal Stent Graft System on April 15th, 2008. As a condition of approval, the FDA has requested a post-approval study. Medtronic has therefore designed a post-approval study, in collaboration with FDA, to document the performance of the Talent Abdominal Stent Graft System under market conditions.

02

Conditions studied

  • Aortic Aneurysm, Abdominal

Keywords

  • Aortic Aneurysm
  • Aneurysm
  • Abdominal Aortic Aneurysm
  • Talent
  • Medtronic
03

In context

Aneurysm

960 studies on the registry are indexed under Aneurysm; 174 are open to participants now.

This study's enrollment of 94 is above the median of 72 across 461 interventional studies indexed under Aneurysm.

Browse Aneurysm studies →

Lead sponsor

Medtronic Cardiovascular is the lead sponsor of 66 studies on the registry; 7 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Subject must have an abdominal aortic aneurysm, with or without iliac involvement.
  • Iliac/femoral access vessel morphology that is compatible with vascular access techniques, devices, and/or accessories;
  • A proximal aortic neck length of ≥ 10mm;
  • Proximal aortic neck angulation ≤ 60°;
  • Distal iliac artery fixation length of ≥ 15mm;
  • An aortic neck diameter of 18-32mm and iliac artery diameters of 8-22mm; and
  • Vessel morphology suitable for endovascular repair.

Exclusion criteria

Exclusion Criteria:

  • Are less than 18 years of age
  • Are pregnant or lactating
  • Have a dominant patent inferior mesenteric artery and an occluded or stenotic celiac and/or superior mesenteric artery
  • Have aneurysmal involvement or occlusion (surgically performed or naturally occurring) of the bilateral internal iliac arteries
  • Have vessels and/or aneurysm dimensions that cannot accommodate the Talent Abdominal Stent Graft as per the indications in Section 3.
  • Have no distal vascular bed (one vessel lower extremity run-off required)
  • Have contraindications for use of contrast medium or anticoagulation drugs
  • Have an uncorrectable coagulopathy
  • Have an SVS/AAVS score greater than 2
  • Have a mycotic aneurysm
  • Have circumferential mural thrombus in the proximal aortic neck
  • Have had a recent (within 3 months) myocardial infarction (MI), cerebral vascular accident (CVA), or major surgical intervention
  • Have traumatic aortic injury
  • Have leaking, pending rupture or ruptured aneurysms
  • Have pseudoaneurysms resulting from previous graft placement
  • Require a revision to previously placed endovascular stent grafts.
  • Have genetic connective tissue disease (e.g., Marfan's or Ehlers-Danlos' Syndromes)
  • Have concomitant thoracic aortic or thoracoabdominal aneurysms
  • Are patients with active systemic infections
  • Are patients who have a condition that threatens to infect the graft.
  • Are patients with sensitivities or allergies to the device materials.
  • Have access vessels (as determined by treating physician) that preclude safe insertion of the delivery system. NOTE: Iliac conduits may be used to ensure the safe insertion of the delivery system.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    Treatment

    Patients diagnosed with an abdominal aortic or aorto-iliac aneurysm that are considered candidates for endovascular repair, per the FDA approved IFU.

    Device: Talent Abdominal Stent Graft

Interventions

  • DeviceTalent Abdominal Stent Graft

    The Talent Abdominal Stent Graft is indicated for the endovascular treatment of abdominal aortic aneurysms with or without iliac involvement.

06

What researchers measure

Primary outcomes

  1. Freedom From Aneurysm-related Mortality (ARM)

    ARM is defined as death from rupture of the abdominal aortic aneurysm or from any procedure intended to treat the Abdominal Aortic Aneurysm (AAA). If a death occurred within 30 days of any procedure intended to treat the AAA, then it is presumed to be aneurysm related unless there is evidence to the contrary. Deaths occurring after 30 days of any procedure intended to treat the AAA that are procedure-related should also be aneurysm related. All deaths were adjudicated by a Clinical Events Committee (CEC) to determine aneurysm, device and/or procedure relatedness.

    Time frame: 5 year Kaplan Meier (KM)

07

Results

Posted Jan 23, 2018

Participant flow

Participant flow — Overall Study
MilestoneTalent Abdominal Stent Graft
Started260
Completed133
Not completed127

Outcome measures

PrimaryFreedom From Aneurysm-related Mortality (ARM)

ARM is defined as death from rupture of the abdominal aortic aneurysm or from any procedure intended to treat the Abdominal Aortic Aneurysm (AAA). If a death occurred within 30 days of any procedure intended to treat the AAA, then it is presumed to be aneurysm related unless there is evidence to the contrary. Deaths occurring after 30 days of any procedure intended to treat the AAA that are procedure-related should also be aneurysm related. All deaths were adjudicated by a Clinical Events Committee (CEC) to determine aneurysm, device and/or procedure relatedness.

Time frame:
5 year Kaplan Meier (KM)
Reported as:
Number · Proportion of participants
Freedom From Aneurysm-related Mortality (ARM)
Proportion of participantsTreatment
Freedom From Aneurysm-related Mortality (ARM).97 (.946 to .994)

Adverse events

Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1. Vitality—31/94 (33%)5/94 (5.3%)
2. ELPS—99/166 (59.6%)112/166 (67.5%)
Most frequent serious events
Showing 10 of 151
Most frequent serious events
Event1. Vitality2. ELPS
Stent-Graft EndoleakGeneral disorders2/9424/166
HaemorrhageVascular disorders0/9410/166
Arterial Occlusive DiseaseVascular disorders5/940/166
Cardiac Failure CongestiveCardiac disorders4/944/166
ArrhythmiaCardiac disorders3/946/166
AnaemiaBlood and lymphatic system disorders3/943/166
Myocardial InfarctionCardiac disorders3/943/166
Renal FailureRenal and urinary disorders3/944/166
SeromaInjury, poisoning and procedural complications0/945/166
Ill-Defined DisorderGeneral disorders0/944/166
Most frequent other events
Most frequent other events
Event1. Vitality2. ELPS
Stent-Graft EndoleakGeneral disorders5/9467/166
AnaemiaBlood and lymphatic system disorders0/9421/166
PyrexiaGeneral disorders0/9421/166
Ill-Defined DisorderGeneral disorders0/9420/166
HaemorrhageVascular disorders0/9420/166
SeromaInjury, poisoning and procedural complications0/9415/166
Back PainMusculoskeletal and connective tissue disorders0/949/166
Renal FailureRenal and urinary disorders0/949/166

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treatment
Mean73.7 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)Treatment
Female33
Male227
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment
Hispanic or Latino6
Not Hispanic or Latino254
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment
American Indian or Alaska Native0
Asian5
Native Hawaiian or Other Pacific Islander0
Black or African American9
White241
More than one race5
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Treatment
United States260
08

Study locations

18 sites
  • USC Univerisity Hospital
    Los Angeles, California 90033, United States
  • Palo Alto VAMC
    Palo Alto, California 94304, United States
  • Christiana Care Health Services
    Newark, Delaware 19713, United States
  • Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
  • Barnes Jewish
    Saint Louis, Missouri 63110, United States
  • St. John's Medical Research Institute
    Springfield, Missouri 65810, United States
  • East Carolina University
    Greenville, North Carolina 27834, United States
  • Forsyth Medical Center
    Winston-Salem, North Carolina 27103, United States
  • Lehigh Valley Hospital
    Allentown, Pennsylvania 18103, United States
  • Pinnacle Health Network
    Harrisburg, Pennsylvania 17110, United States
  • Sanford USD Medical Center
    Sioux Falls, South Dakota 57104, United States
  • North Central Heart Institute
    Sioux Falls, South Dakota 57108, United States
  • St. Mary's Medical Center
    Knoxville, Tennessee 37923, United States
  • Vanderbilt Vascular Surgery
    Nashville, Tennessee 37232, United States
  • Wilford Hall Medical Center
    Lackland Air Force Base, Texas 78236, United States
  • Inova Fairfax Hospital
    Falls Church, Virginia 22042, United States
  • Charleston Area Medical Center
    Charleston, West Virginia 23504, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00816062
Lead sponsor
Medtronic Cardiovascular
Responsible party
Sponsor
First posted
Dec 31, 2008
Start date
Dec 2008
Primary completion
Jul 2015
Completion
Jul 2015
Results posted
Jan 23, 2018
Last update
Oct 29, 2021

Study contacts

Luis Sanchez, MD
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion